Cargando…
Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggest...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829527/ https://www.ncbi.nlm.nih.gov/pubmed/29527165 http://dx.doi.org/10.3389/fphar.2018.00113 |
_version_ | 1783302823296892928 |
---|---|
author | Turobov, Valery I. Danilkovich, Alexey V. Shevelev, Alexei B. Biryukova, Yulia K. Pozdniakova, Natalia V. Azev, Viatcheslav N. Murashev, Arkady N. Lipkin, Valery M. Udovichenko, Igor P. |
author_facet | Turobov, Valery I. Danilkovich, Alexey V. Shevelev, Alexei B. Biryukova, Yulia K. Pozdniakova, Natalia V. Azev, Viatcheslav N. Murashev, Arkady N. Lipkin, Valery M. Udovichenko, Igor P. |
author_sort | Turobov, Valery I. |
collection | PubMed |
description | Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These in vivo experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats. |
format | Online Article Text |
id | pubmed-5829527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58295272018-03-09 Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis Turobov, Valery I. Danilkovich, Alexey V. Shevelev, Alexei B. Biryukova, Yulia K. Pozdniakova, Natalia V. Azev, Viatcheslav N. Murashev, Arkady N. Lipkin, Valery M. Udovichenko, Igor P. Front Pharmacol Pharmacology Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These in vivo experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats. Frontiers Media S.A. 2018-02-23 /pmc/articles/PMC5829527/ /pubmed/29527165 http://dx.doi.org/10.3389/fphar.2018.00113 Text en Copyright © 2018 Turobov, Danilkovich, Shevelev, Biryukova, Pozdniakova, Azev, Murashev, Lipkin and Udovichenko. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Turobov, Valery I. Danilkovich, Alexey V. Shevelev, Alexei B. Biryukova, Yulia K. Pozdniakova, Natalia V. Azev, Viatcheslav N. Murashev, Arkady N. Lipkin, Valery M. Udovichenko, Igor P. Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title_full | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title_fullStr | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title_full_unstemmed | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title_short | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis |
title_sort | efficacy of synthetic peptide corresponding to the acth-like sequence of human immunoglobulin g1 in experimental autoimmune encephalomyelitis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829527/ https://www.ncbi.nlm.nih.gov/pubmed/29527165 http://dx.doi.org/10.3389/fphar.2018.00113 |
work_keys_str_mv | AT turobovvaleryi efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT danilkovichalexeyv efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT shevelevalexeib efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT biryukovayuliak efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT pozdniakovanataliav efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT azevviatcheslavn efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT murashevarkadyn efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT lipkinvalerym efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis AT udovichenkoigorp efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis |